BACKGROUND: The Common Terminology Criteria for Adverse Events (CTCAE) are used as standard practice in trials of cancer treatments by clinicians to elicit and report toxic effects. Alternatively, patients could report this information directly as patient-reported outcomes, but the accuracy of these reports compared with clinician reports remains unclear. We aimed to compare the reporting of symptom severity reported by patients and clinicians. METHODS: Between March and May, 2005, a questionnaire with 11 common CTCAE symptoms was given to consecutive outpatients and their clinicians (physicians and nurses) in lung and genitourinary cancer clinics in the Memorial Sloan-Kettering Cancer Center, New York, NY, USA. Patients completed a version that used language adapted from the CTCAE for patient self-reporting. The results from the questionnaire were compared with clinician reporting of the same symptoms. FINDINGS: Of 435 patients and their clinicians asked to take part in the study, 400 paired surveys were completed. For most symptoms, agreement between patient and clinician was high, and most discrepancies were within a grade difference of one point. Agreement was higher for symptoms that could be observable directly, such as vomiting and diarrhoea, than for more subjective symptoms, such as fatigue and dyspnoea. Differences in symptom reporting rarely would have changed treatment decisions or dosing, and patients assigned greater severity to symptoms more than did clinicians. No significant differences were recorded between the results when the questionnaire was completed by the patient before or after the clinician. INTERPRETATION: Patient reporting of symptoms could add to the current approach to symptom monitoring in cancer treatment trials. Future research should assess the effect of self reporting on clinical outcomes and efficiency, and the use of real-time collection of patient-reported outcomes for early detection of potentially serious adverse events.
BACKGROUND: The Common Terminology Criteria for Adverse Events (CTCAE) are used as standard practice in trials of cancer treatments by clinicians to elicit and report toxic effects. Alternatively, patients could report this information directly as patient-reported outcomes, but the accuracy of these reports compared with clinician reports remains unclear. We aimed to compare the reporting of symptom severity reported by patients and clinicians. METHODS: Between March and May, 2005, a questionnaire with 11 common CTCAE symptoms was given to consecutive outpatients and their clinicians (physicians and nurses) in lung and genitourinary cancer clinics in the Memorial Sloan-Kettering Cancer Center, New York, NY, USA. Patients completed a version that used language adapted from the CTCAE for patient self-reporting. The results from the questionnaire were compared with clinician reporting of the same symptoms. FINDINGS: Of 435 patients and their clinicians asked to take part in the study, 400 paired surveys were completed. For most symptoms, agreement between patient and clinician was high, and most discrepancies were within a grade difference of one point. Agreement was higher for symptoms that could be observable directly, such as vomiting and diarrhoea, than for more subjective symptoms, such as fatigue and dyspnoea. Differences in symptom reporting rarely would have changed treatment decisions or dosing, and patients assigned greater severity to symptoms more than did clinicians. No significant differences were recorded between the results when the questionnaire was completed by the patient before or after the clinician. INTERPRETATION:Patient reporting of symptoms could add to the current approach to symptom monitoring in cancer treatment trials. Future research should assess the effect of self reporting on clinical outcomes and efficiency, and the use of real-time collection of patient-reported outcomes for early detection of potentially serious adverse events.
Authors: Stephanie L Pugh; Joseph P Rodgers; Katherine A Yeager; Ronald C Chen; Benjamin Movsas; Roseann Bonanni; James Dignam; Deborah W Bruner Journal: Int J Radiat Oncol Biol Phys Date: 2020-06-24 Impact factor: 7.038
Authors: Tamara P Miller; Brian T Fisher; Kelly D Getz; Leah Sack; Hanieh Razzaghi; Alix E Seif; Rochelle Bagatell; Peter C Adamson; Richard Aplenc Journal: Pediatr Blood Cancer Date: 2019-04-09 Impact factor: 3.167
Authors: Amylou C Dueck; Tito R Mendoza; Sandra A Mitchell; Bryce B Reeve; Kathleen M Castro; Lauren J Rogak; Thomas M Atkinson; Antonia V Bennett; Andrea M Denicoff; Ann M O'Mara; Yuelin Li; Steven B Clauser; Donna M Bryant; James D Bearden; Theresa A Gillis; Jay K Harness; Robert D Siegel; Diane B Paul; Charles S Cleeland; Deborah Schrag; Jeff A Sloan; Amy P Abernethy; Deborah W Bruner; Lori M Minasian; Ethan Basch Journal: JAMA Oncol Date: 2015-11 Impact factor: 31.777
Authors: Jinbo Yue; Qiuling Shi; Ting Xu; Melenda Jeter; Ting-Yu Chen; Ritsuko Komaki; Daniel R Gomez; Tinsu Pan; Charles S Cleeland; Zhongxing Liao; Xin Shelley Wang Journal: Qual Life Res Date: 2018-03-16 Impact factor: 4.147
Authors: Christopher R Friese; Alex J Fauer; Clare Kuisell; Kari Mendelsohn-Victor; Nathan C Wright; Jennifer J Griggs; Milisa Manojlovich Journal: Health Serv Res Date: 2020-10-30 Impact factor: 3.402
Authors: Gita Thanarajasingam; Lori M Minasian; Frederic Baron; Franco Cavalli; R Angelo De Claro; Amylou C Dueck; Tarec C El-Galaly; Neil Everest; Jan Geissler; Christian Gisselbrecht; John Gribben; Mary Horowitz; S Percy Ivy; Caron A Jacobson; Armand Keating; Paul G Kluetz; Aviva Krauss; Yok Lam Kwong; Richard F Little; Francois-Xavier Mahon; Matthew J Matasar; María-Victoria Mateos; Kristen McCullough; Robert S Miller; Mohamad Mohty; Philippe Moreau; Lindsay M Morton; Sumimasa Nagai; Simon Rule; Jeff Sloan; Pieter Sonneveld; Carrie A Thompson; Kyriaki Tzogani; Flora E van Leeuwen; Galina Velikova; Diego Villa; John R Wingard; Sophie Wintrich; John F Seymour; Thomas M Habermann Journal: Lancet Haematol Date: 2018-06-18 Impact factor: 18.959